References
- Rubin P C. Beta blockers in pregnancy. New Engl J Med 1981; 305: 1323–1326
- Krauer B, Krauer F, Hytten F E. Drug disposition and pharmacokinetics in the maternal placental fetal unit. Pharmacol Ther 1980; 10: 301–342
- O'Hare N F, Leahey W, Murnaghan G A, McDevitt D G. Pharmacokinetics of sotalol during pregnancy. Eur J Clin Pharmac 1983; 24: 521–524
- Rubin P C, Butters L, Kelman A W, Fitzsimmons C, Reid J L. Labetalol disposition and concentration effect relationships during pregnancy. Br J Clin Pharmac 1983; 15: 465–470
- Rubin P C, Butters L, Clark D M, Reynolds B, Sumner D J, Steedman D, Low R A, Reid J L. Placebo controlled trial of atenolol in the treatment of pregnancy associated hypertension. Lancet 1983; 1: 431–434
- Rubin P C, Butters L, Clark D, Low R A, Reid J L. Obstetric aspects of the use during pregnancy of atenolol, Submitted
- Gallery E DM, Saunders D M, Hunyor S, Gyory A Z. Randomised comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J 1979; 1: 1591–1594
- Fidler J, Smith V, Fayers P, de Swiet M. Randomised controlled comparative study of methyldopa and oxprenolol in treatment of hypertension in pregnancy. Br Med J 1983; 286: 1927–1930
- Redman C WG. A controlled trial of the treatment of hypertension in pregnancy: labetalol compared with methyldopa. The investigation of labetalol in the management of hypertension in pregnancy, A Reilly, E M Symonds. Excerpta Medica, Amsterdam 1982
- Redman C WG, Beilin L J, Bonnar J, Ounsted N K. Fetal outcome in trial of antihypertensive treatment in pregnancy. Lancet 1976; 2: 753–756